Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial (French Language Version)
2016 Gastrointestinal Cancers Symposium
Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses in French the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490).
James L. Abbruzzese, MD
James L. Abbruzzese, MD, of Duke University, discusses the international outlook on patterns of care and their impact on outcomes.
Jonathan R. Strosberg, MD
Jonathan R. Strosberg, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses progression-free survival, radiographic response, and preliminary overall survival findings of this phase III study on midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 194).
Dung T. Le, MD
Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, discusses study findings on the safety and activity of nivolumab monotherapy in advanced and metastatic gastric or gastroesophageal junction cancer (Abstract 6).
Krzysztof Bujko, MD
Krzysztof Bujko, MD, of the Maria Skłodowska Curie Memorial Cancer Centre, discusses the results of a multicenter Polish study on neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer (Abstract 489).
Somnath Mukherjee, MD
Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based chemoradiation as a pre-operative regimen for resectable esophageal cancer.. (Abstract 3).